Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis

3 Feb 2020

Abstract excerpt

Abstract Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5 (IL-5) that reduces blood eosinophil counts, as an add-on therapy to glucocorticoid treatment, results in more accrued weeks in remission, reductions in glucocorticoid use and reductions in relapse rate. However, treatment response varies across a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Eosinophilic Disorders and Syndromes
Share to Eosinophilic Esophagitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32009195
DOI: 10.1007/s00296-020-04523-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitisPMID 32009195Read ↗

Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status.Semantic proximity Read ↗

Genetically distinct clinical subsets, and associations with asthma and eosinophil abundance, within Eosinophilic Granulomatosis with PolyangiitisSemantic proximity Read ↗

Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis.Semantic proximity Read ↗

Can genetic studies predict treatment response in antineutrophil cytoplasmic antibody-associated vasculitis?Semantic proximity Read ↗

Genetic associations of eosinophilic granulomatosis with polyangiitis in the Japanese population: Exploring similarities and differences with European populationsSemantic proximity Read ↗

Gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.Semantic proximity Read ↗

Genetic associations of eosinophilic granulomatosis with polyangiitis in the Japanese population: exploring similarities and differences with European populations.Semantic proximity Read ↗

SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.Semantic proximity Read ↗

Eosinophil-Linked Hyperdynamic Circulation in EGPA Improves under Anti-IL-5 Therapy: A Longitudinal StudySemantic proximity Read ↗

Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis.Semantic proximity Read ↗

Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis.Semantic proximity Read ↗

ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.